Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hansson

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Nature Communications|April 27, 2018
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expressionMina Ali, Ram Ajore, Anna-Karin Wihlborg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaMarkus Hansson, Peter Gimsing, Ashraf Badros, et al.
Leukemia|November 18, 2025
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset casesMaroulio Pertesi, Delphine Demangel, Abhishek Niroula, et al.
Cancer Medicine|April 20, 2018
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myelomaJohan Lund, Astrid Gruber, Birgitta Lauri, et al.
Haematologica|July 29, 2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, et al.
Blood Advances|January 4, 2018
Direct evidence for a polygenic etiology in familial multiple myelomaBritt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, et al.
European Journal of Haematology|September 18, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study GroupHenrik Gregersen, Valdas Peceliunas, Kari Remes, et al.
Blood Advances|December 22, 2020
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trialRowan Kuiper, Sonja Zweegman, Mark van Duin, et al.
The New England Journal of Medicine|August 27, 2015
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaHenk M Lokhorst, Torben Plesner, Jacob P Laubach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPaul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Nature Communications|April 27, 2018
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expressionMina Ali, Ram Ajore, Anna-Karin Wihlborg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple MyelomaMarkus Hansson, Peter Gimsing, Ashraf Badros, et al.
Leukemia|November 18, 2025
Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset casesMaroulio Pertesi, Delphine Demangel, Abhishek Niroula, et al.
Cancer Medicine|April 20, 2018
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myelomaJohan Lund, Astrid Gruber, Birgitta Lauri, et al.
Haematologica|July 29, 2017
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i>. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, et al.
Blood Advances|January 4, 2018
Direct evidence for a polygenic etiology in familial multiple myelomaBritt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, et al.
European Journal of Haematology|September 18, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study GroupHenrik Gregersen, Valdas Peceliunas, Kari Remes, et al.
Blood Advances|December 22, 2020
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trialRowan Kuiper, Sonja Zweegman, Mark van Duin, et al.
The New England Journal of Medicine|August 27, 2015
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaHenk M Lokhorst, Torben Plesner, Jacob P Laubach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPaul G Richardson, Shaji K Kumar, Tamás Masszi, et al.
Pageof 9